The opposite is actually true. Because the company is seeking approval in 4 jurisdictions they increase the odds of regulatory approval. It’s like 4 shots on goal...actually 8 because it appears that they are also seeking approval for rGBM, which is a MUCH larger market with no effective treatment options.